With Opsumit launch rolling, Actelion doesn’t ‘need’ M&A: CEO

Carly Helfand

Back in 2013, launched , a new-and-improved pulmonary arterial hypertension drug it hoped would help make up sales for its aging Tracleer. And so far, everything is going according to plan.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS